• Explore /
  • Poster
  • / ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).

ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).

Abstract Poster

Authors

null

Olalekan O. Oluwole

Vanderbilt-Ingram Cancer Center, Nashville, TN

Olalekan O. Oluwole , Michael Russell Bishop , Christian Gisselbrecht , Leo I. Gordon , Marie Jose Kersten , David G. Maloney , Norbert Schmitz , María Dolores Caballero Barrigon , John Kuruvilla , Kevin W. Song , Caron A. Jacobson , Loretta J. Nastoupil , Peter Riedell , Yizhou Jiang , John M. Rossi , Lillian Lee , Paul C. Cheng , Frederick Lundry Locke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03391466

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS7585)

DOI

10.1200/JCO.2018.36.15_suppl.TPS7585

Abstract #

TPS7585

Poster Bd #

220a

Abstract Disclosures

Similar Posters

First Author: Michael Wang

First Author: Ian W. Flinn

First Author: Sattva Swarup Neelapu

First Author: Bijal D. Shah